TF 6450

Drug Profile

TF 6450

Alternative Names: TD-6450; TF-6450

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Theravance
  • Developer Innoviva; Trek Therapeutics
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 15 Sep 2016 Efficacy and adverse events data from a phase II a trial in Hepatitis C released by Trek Therapeutics
  • 17 Mar 2016 Trek Therapeutics plans a phase II trial for Hepatitis C(Combination therapy, Treatment-naive) in New Zealand (PO) (NCT02716428)
  • 27 Oct 2015 TF 6450 licensed to Trek Therapeutics worldwide for Hepatitis C (Combination therapy) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top